Biotech Values

[DewDiligence]

SGP Says Direct Thrombin Inhibitor Has Big Potential

[The comment came on today’s CC in reply to a question about what is interesting in SGP’s mid-stage pipeline. The answer was notable in that Hassan did not mention the HCV PI until prompted to comment on it.]

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061020:MTFH85338_2...

>>
Fri Oct 20, 2006 9:05 AM ET

NEW YORK, Oct 20 (Reuters) - Fred Hassan, the chief executive of Schering-Plough Corp. <SGP>, on Friday said he has high hopes an experimental company drug to prevent blood clots will be launched in 2010 or 2011 and become a big seller.

The once-a-day oral drug, which blocks receptors to a protein called thrombin involved in blood clotting, is now in mid-stage studies.

Hassan told analysts in a conference call the so-called thrombin receptor antagonist (TRA) could achieve annual sales "past the $1 billion" mark, if approved, which would qualify it for blockbuster status.
<<